Where Does Genzyme See Alemtuzumab For MS? After Gilenya, Before Tysabri
Genzyme laid out its strategy for getting alemtuzumab to peak sales of $3.5 billion in an effort to convince investors - and Sanofi - that it's worth more money.
Genzyme laid out its strategy for getting alemtuzumab to peak sales of $3.5 billion in an effort to convince investors - and Sanofi - that it's worth more money.